Skip to content

Biohaven BHVN Operating Cash Flow

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$5.33B+220%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$88.9M-44.2%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$13.06M+35.5%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$132.39M-69.5%
uniQure logo
uniQureQURE
-$38.24M+13.3%
Roivant Sciences logo
Roivant SciencesROIV
-$163.82M+5.1%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's operating cash flow?
Biohaven (BHVN) reported operating cash flow of -$149.92M in Q1 2026.
How has Biohaven's operating cash flow changed year-over-year?
Biohaven's operating cash flow increased by 9.2% year-over-year, from -$165.12M to -$149.92M.
What is the long-term trend for Biohaven's operating cash flow?
Over 3 years (2022 to 2025), Biohaven's operating cash flow has grown at a 27.0% compound annual growth rate (CAGR), from -$297.69M to -$609.44M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.